… Background: ALC showed promising efficacy and tolerability in the phase I/II study (AF-…
PFS) of ALC to CRZ in ALK+ NSCLC patients (pts) without prior ALK inhibitor treatment. Methods: …

… Background: ALK inhibitors are the standard treatment for ALK+ NSCLC and the comparison
between 2 ALK inhibitors will be valuable in determining therapeutic strategy for ALK+ …

… and crizotinib against brain metastases and whether ALK inhibition maintains efficacy
specifically in the setting of CNS progression treated locally (NCT02075840). This latter point is of …

… tyrosine kinase inhibitor. In the J-ALEX study, ALC proved superior efficacy and tolerability
… Methods: Patients with advanced ALK+ NSCLC were randomized 1:1 to receive ALC 300 …

… of alectinib in ALK+ NSCLC patients, outline its clinical development, and CNS activity, and
comment on the place of alectinib in the management of ALK… alectinib or other ALK inhibitors. …

… -positive metastatic NSCLC whose disease has progressed on crizotinib and at least one
other ALK inhibitor; or alectinib or ceritinib as the first ALK inhibitor therapy for metastatic …

… ALK inhibitors compared to chemotherapy (ALK vs. chemo) and 2nd generation ALK inhibitors
compared to 1 st generation ALK inhibitors (… study of alectinib (ALC) vs. crizotinib (CRZ) in …

… ) who might have derived greater benefit from alectinib than crizotinib, by more potent ALK
inhibition. … Alectinib (ALC) versus crizotinib (CRZ) in ALK-positive non-small cell lung cancer (…

… ALK inhibition as a therapeutic strategy in ALK-rearranged NSCLC management, with a focus
on a specific ALK–TKI, alectinib… data about ALK inhibition as a therapeutic strategy in ALK-…

… received ALC as a 1st subsequent therapy, whereas only 10.7% of patients in the ALC arm
received CRZ. Conclusions: In this final J-ALEX OS analysis, prolongation of OS in the ALC …